Zevra Therapeutics, Inc. (ZVRA) Tops Q2 EPS by 16c, beats revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ZVRA Hot Sheet
Join SI Premium – FREE
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q2 EPS of ($0.15), $0.16 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $3.07 million.
For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enlight Renewable Energy Ltd (ENLT) Tops Q3 EPS by 11c; Offers Guidance
- Sequans Communications (SQNS) Tops Q3 EPS by 42c
- Xenia Hotels (XHR) Tops Q3 EPS by 8c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
